Cosela (trilaciclib), first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression
14 Febbraio 2021
The FDA has approved Cosela (trilaciclib) as the first therapy in its class to reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving
